Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 53

1.

The anti-cancer activity of a first-in-class small molecule targeting PCNA.

Gu L, Lingeman RG, Yakushijin F, Sun E, Cui Q, Chao J, Hu W, Li H, Hickey RJ, Stark JM, Yuan YC, Chen Y, Vonderfecht SL, Synold TW, Shi Y, Reckamp KL, Horne D, Malkas LH.

Clin Cancer Res. 2018 Jul 2. pii: clincanres.0592.2018. doi: 10.1158/1078-0432.CCR-18-0592. [Epub ahead of print]

PMID:
29967249
2.

Real-World Pseudoprogression: an Uncommon Phenomenon.

Reckamp KL.

J Thorac Oncol. 2018 Jul;13(7):880-882. doi: 10.1016/j.jtho.2018.05.011. No abstract available.

PMID:
29935844
3.

Targeted Therapy for Patients With Metastatic Non-Small Cell Lung Cancer.

Reckamp KL.

J Natl Compr Canc Netw. 2018 May;16(5S):601-604. doi: 10.6004/jnccn.2018.0046.

PMID:
29784736
4.

Ensartinib (X-396) in ALK-Positive Non-Small Cell Lung Cancer: Results from a First-in-Human Phase I/II, Multicenter Study.

Horn L, Infante JR, Reckamp KL, Blumenschein GR, Leal TA, Waqar SN, Gitlitz BJ, Sanborn RE, Whisenant JG, Du L, Neal JW, Gockerman JP, Dukart G, Harrow K, Liang C, Gibbons JJ, Holzhausen A, Lovly CM, Wakelee HA.

Clin Cancer Res. 2018 Jun 15;24(12):2771-2779. doi: 10.1158/1078-0432.CCR-17-2398. Epub 2018 Mar 21.

PMID:
29563138
5.

Hybrid Capture-Based Comprehensive Genomic Profiling Identifies Lung Cancer Patients with Well-Characterized Sensitizing Epidermal Growth Factor Receptor Point Mutations That Were Not Detected by Standard of Care Testing.

Suh JH, Schrock AB, Johnson A, Lipson D, Gay LM, Ramkissoon S, Vergilio JA, Elvin JA, Shakir A, Ruehlman P, Reckamp KL, Ou SI, Ross JS, Stephens PJ, Miller VA, Ali SM.

Oncologist. 2018 Mar 14. pii: theoncologist.2017-0493. doi: 10.1634/theoncologist.2017-0493. [Epub ahead of print]

PMID:
29540602
6.

Urine test for EGFR analysis in patients with non-small cell lung cancer.

Franovic A, Raymond VM, Erlander MG, Reckamp KL.

J Thorac Dis. 2017 Oct;9(Suppl 13):S1323-S1331. doi: 10.21037/jtd.2017.06.144. Review.

7.

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE.

J Clin Oncol. 2017 Dec 10;35(35):3924-3933. doi: 10.1200/JCO.2017.74.3062. Epub 2017 Oct 12.

PMID:
29023213
8.

Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).

Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE; Alliance for Clinical Trials in Oncology.

J Clin Oncol. 2017 Jul 1;35(19):2184-2192. doi: 10.1200/JCO.2016.71.3743. Epub 2017 May 10.

9.

Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer: A Randomized, Multicenter Phase II Trial.

Kim DW, Tiseo M, Ahn MJ, Reckamp KL, Hansen KH, Kim SW, Huber RM, West HL, Groen HJM, Hochmair MJ, Leighl NB, Gettinger SN, Langer CJ, Paz-Ares Rodríguez LG, Smit EF, Kim ES, Reichmann W, Haluska FG, Kerstein D, Camidge DR.

J Clin Oncol. 2017 Aug 1;35(22):2490-2498. doi: 10.1200/JCO.2016.71.5904. Epub 2017 May 5.

PMID:
28475456
10.

Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.

Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM.

Clin Cancer Res. 2017 Aug 15;23(16):4556-4568. doi: 10.1158/1078-0432.CCR-16-2821. Epub 2017 May 3.

PMID:
28468947
11.

Immunotherapy improves the prognosis of lung cancer: do we have to change intensive care unit admission and triage guidelines?

Guillon A, Reckamp KL, Heuzé-Vourc'h N.

Crit Care. 2017 Jan 27;21(1):18. doi: 10.1186/s13054-017-1602-8. No abstract available.

12.

PS01.69: Indirect Naive Comparison of ALK Inhibitors for ALK+ Non-Small Cell Lung Cancer (NSCLC) Post-Crizotinib Failure: Topic: Medical Oncology.

Reckamp KL, Huang J, Huang H, Moore Y.

J Thorac Oncol. 2016 Nov;11(11S):S313-S314. doi: 10.1016/j.jtho.2016.09.104. Epub 2016 Oct 28. No abstract available.

13.

PS01.66: Biomarker Stratification of Outcomes of Third-Generation EGFR TKI Therapy in Patients with Previously-Treated Advanced NSCLC: Topic: Medical Oncology.

Wakelee H, Goldman JW, Gadgeel S, Camidge DR, Reckamp KL, Ou SI, Yu HA, Solomon B, Liu SV, Pérol M, Dupuis NF, Nickel A, Karlovich C, Raponi M, Yurasov S, Litten J, Despain D, Soria JC, Sequist L, Carbone D.

J Thorac Oncol. 2016 Nov;11(11S):S311-S312. doi: 10.1016/j.jtho.2016.09.101. Epub 2016 Oct 28. No abstract available.

14.

MINI01.02: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X-396) in Patients (pts) with ALK+ NSCLC: Topic: Medical Oncology.

Horn L, Wakelee H, Reckamp KL, Blumenschein G Jr, Infante JR, Carter CA, Waqar SN, Neal JW, Harrow K, Gockerman JP, Dukart G, Liang C, Gibbons JL, Hernandez J, Newman-Eerkes T, Lim L, Lovly CM.

J Thorac Oncol. 2016 Nov;11(11S):S256-S257. doi: 10.1016/j.jtho.2016.09.017. Epub 2016 Oct 28. No abstract available.

15.

A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.

Gandara DR, Leighl N, Delord JP, Barlesi F, Bennouna J, Zalcman G, Infante JR, Reckamp KL, Kelly K, Shepherd FA, Mazieres J, Janku F, Gardner OS, Mookerjee B, Wu Y, Cox DS, Schramek D, Peddareddigari V, Liu Y, D'Amelio AM Jr, Blumenschein G Jr.

J Thorac Oncol. 2017 Mar;12(3):556-566. doi: 10.1016/j.jtho.2016.11.2218. Epub 2016 Nov 19.

16.

A Highly Sensitive and Quantitative Test Platform for Detection of NSCLC EGFR Mutations in Urine and Plasma.

Reckamp KL, Melnikova VO, Karlovich C, Sequist LV, Camidge DR, Wakelee H, Perol M, Oxnard GR, Kosco K, Croucher P, Samuelsz E, Vibat CR, Guerrero S, Geis J, Berz D, Mann E, Matheny S, Rolfe L, Raponi M, Erlander MG, Gadgeel S.

J Thorac Oncol. 2016 Oct;11(10):1690-700. doi: 10.1016/j.jtho.2016.05.035. Epub 2016 Jul 25.

17.

Therapeutic monoclonal antibodies for respiratory diseases: Current challenges and perspectives, March 31 - April 1, 2016, Tours, France.

Desoubeaux G, Reichert JM, Sleeman M, Reckamp KL, Ryffel B, Adamczewski JP, Sweeney TD, Vanbever R, Diot P, Owen CA, Page C, Lerondel S, Le Pape A, Heuze-Vourc'h N.

MAbs. 2016 Aug-Sep;8(6):999-1009. doi: 10.1080/19420862.2016.1196521. Epub 2016 Jun 6.

18.

Advances in immunotherapy for non-small cell lung cancer.

Reckamp KL.

Clin Adv Hematol Oncol. 2015 Dec;13(12):847-53. Review.

PMID:
27058851
19.

Selumetinib with and without erlotinib in KRAS mutant and KRAS wild-type advanced nonsmall-cell lung cancer.

Carter CA, Rajan A, Keen C, Szabo E, Khozin S, Thomas A, Brzezniak C, Guha U, Doyle LA, Steinberg SM, Xi L, Raffeld M, Tomita Y, Lee MJ, Lee S, Trepel JB, Reckamp KL, Koehler S, Gitlitz B, Salgia R, Gandara D, Vokes E, Giaccone G.

Ann Oncol. 2016 Apr;27(4):693-9. doi: 10.1093/annonc/mdw008. Epub 2016 Jan 22.

20.

Serum LAMC2 enhances the prognostic value of a multi-parametric panel in non-small cell lung cancer.

Korbakis D, Dimitromanolakis A, Prassas I, Davis GJ, Barber E, Reckamp KL, Blasutig I, Diamandis EP.

Br J Cancer. 2015 Jul 28;113(3):484-91. doi: 10.1038/bjc.2015.171. Epub 2015 Jul 16.

21.

Phase II Study of the AKT Inhibitor MK-2206 plus Erlotinib in Patients with Advanced Non-Small Cell Lung Cancer Who Previously Progressed on Erlotinib.

Lara PN Jr, Longmate J, Mack PC, Kelly K, Socinski MA, Salgia R, Gitlitz B, Li T, Koczywas M, Reckamp KL, Gandara DR.

Clin Cancer Res. 2015 Oct 1;21(19):4321-6. doi: 10.1158/1078-0432.CCR-14-3281. Epub 2015 Jun 23.

22.

Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.

Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett SM.

Cancer. 2015 Sep 15;121(18):3298-306. doi: 10.1002/cncr.29480. Epub 2015 May 29.

23.

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, Waterhouse D, Ready N, Gainor J, Arén Frontera O, Havel L, Steins M, Garassino MC, Aerts JG, Domine M, Paz-Ares L, Reck M, Baudelet C, Harbison CT, Lestini B, Spigel DR.

N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.

24.

Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors.

Koczywas M, Frankel PH, Synold TW, Lenz HJ, Mortimer JE, El-Khoueiry AB, Gandara DR, Cristea MC, Chung VM, Lim D, Reckamp KL, Lau DH, Doyle LA, Ruel C, Carroll MI, Newman EM.

Br J Cancer. 2014 Dec 9;111(12):2268-74. doi: 10.1038/bjc.2014.554. Epub 2014 Oct 28.

25.

Future of ALK inhibition in non-small-cell lung cancer.

Reckamp KL.

Lancet Oncol. 2014 Sep;15(10):1047-9. doi: 10.1016/S1470-2045(14)70390-0. Epub 2014 Aug 18. No abstract available. Erratum in: Lancet Oncol. 2014 Oct;15(11):e475.

PMID:
25153539
26.

The FEN1 E359K germline mutation disrupts the FEN1-WRN interaction and FEN1 GEN activity, causing aneuploidy-associated cancers.

Chung L, Onyango D, Guo Z, Jia P, Dai H, Liu S, Zhou M, Lin W, Pang I, Li H, Yuan YC, Huang Q, Zheng L, Lopes J, Nicolas A, Chai W, Raz D, Reckamp KL, Shen B.

Oncogene. 2015 Feb 12;34(7):902-11. doi: 10.1038/onc.2014.19. Epub 2014 Mar 10.

27.

A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.

Reckamp KL, Giaccone G, Camidge DR, Gadgeel SM, Khuri FR, Engelman JA, Koczywas M, Rajan A, Campbell AK, Gernhardt D, Ruiz-Garcia A, Letrent S, Liang J, Taylor I, O'Connell JP, Jänne PA.

Cancer. 2014 Apr 15;120(8):1145-54. doi: 10.1002/cncr.28561. Epub 2014 Feb 5.

28.

PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.

Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, Garon EB, Lenburg ME, Sharma S, Spira AE, Elashoff D, Dubinett SM.

Mol Cancer Res. 2014 May;12(5):765-74. doi: 10.1158/1541-7786.MCR-13-0377. Epub 2014 Jan 27.

29.

EGFR-mutated lung cancer with T790M-acquired resistance in the brain and histologic transformation in the lung.

Scher KS, Saldivar JS, Fishbein M, Marchevsky A, Reckamp KL.

J Natl Compr Canc Netw. 2013 Sep 1;11(9):1040-4.

PMID:
24029120
30.

Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer.

Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF 2nd, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett SM.

Am J Transl Res. 2013 Aug 15;5(5):481-96. eCollection 2013.

31.

Myeloid clusters are associated with a pro-metastatic environment and poor prognosis in smoking-related early stage non-small cell lung cancer.

Zhang W, Pal SK, Liu X, Yang C, Allahabadi S, Bhanji S, Figlin RA, Yu H, Reckamp KL.

PLoS One. 2013 May 24;8(5):e65121. doi: 10.1371/journal.pone.0065121. Print 2013.

32.

Intraventricular chemotherapy for leptomeningeal carcinomatosis from lung cancer: a feasible and beneficial treatment option?

Christoph DC, Reckamp KL.

J Thorac Oncol. 2013 May;8(5):523-4. doi: 10.1097/JTO.0b013e31828b518a. No abstract available.

33.

A 75-year-old man with progressive bronchioalveolar carcinoma.

Baikadi M, Lovly C, Horn L, Reckamp KL, Noonan K, Laskin J, Morris GJ.

Semin Oncol. 2013 Feb;40(1):e1-8. doi: 10.1053/j.seminoncol.2012.11.004. No abstract available.

PMID:
23391120
34.

Phosphatidylinositol-3-kinase pathway.

Reckamp KL.

J Thorac Oncol. 2012 Dec;7(16 Suppl 5):S383-4. doi: 10.1097/JTO.0b013e31826df11c. Review. No abstract available.

35.

Is benefit of maintenance therapy for NSCLC best defined by progression-free survival?

Reckamp KL.

Lancet Oncol. 2012 May;13(5):435-6. doi: 10.1016/S1470-2045(12)70157-2. Epub 2012 Apr 17. No abstract available.

PMID:
22512846
36.

Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer.

Reckamp KL.

Cancer Lett. 2012 Aug 28;321(2):101-9. doi: 10.1016/j.canlet.2012.01.041. Epub 2012 Feb 3. Review.

PMID:
22306704
37.

(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib.

Benz MR, Herrmann K, Walter F, Garon EB, Reckamp KL, Figlin R, Phelps ME, Weber WA, Czernin J, Allen-Auerbach MS.

J Nucl Med. 2011 Nov;52(11):1684-1689. doi: 10.2967/jnumed.111.095257.

38.

Novel mechanisms and targets: miscellaneous agents.

Reckamp KL.

J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1812-4. doi: 10.1097/01.JTO.0000407569.29900.73. No abstract available.

39.

Combination chemotherapy for older adults with advanced non-small-cell lung cancer.

Reckamp KL.

Lancet. 2011 Sep 17;378(9796):1055-7. doi: 10.1016/S0140-6736(11)61259-2. Epub 2011 Aug 8. No abstract available.

PMID:
21831419
40.

Management of non-small-cell lung cancer in the older adult.

VanderWalde A, Pal SK, Reckamp KL.

Maturitas. 2011 Apr;68(4):311-21. doi: 10.1016/j.maturitas.2011.01.008. Epub 2011 Feb 3. Review.

PMID:
21295421
41.

Mammalian target of rapamycin, Akt, and phosphatidylinositol 3-kinase signaling.

Pal SK, Reckamp KL.

J Thorac Oncol. 2010 Dec;5(12 Suppl 6):S487-9. doi: 10.1097/01.JTO.0000391378.17179.8f. No abstract available.

42.

CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer.

Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, Strieter RM.

BMC Cancer. 2009 Jun 29;9:213. doi: 10.1186/1471-2407-9-213.

43.

The role of targeting mammalian target of rapamycin in lung cancer.

Pal SK, Figlin RA, Reckamp KL.

Clin Lung Cancer. 2008 Nov;9(6):340-5. doi: 10.3816/CLC.2008.n.049. Review.

PMID:
19073516
44.

Non-small cell lung cancer in the elderly: defining treatment options.

Vora N, Reckamp KL.

Semin Oncol. 2008 Dec;35(6):590-6. doi: 10.1053/j.seminoncol.2008.08.009. Review.

45.

Chemokines as therapeutic targets in renal cell carcinoma.

Reckamp KL, Strieter RM, Figlin RA.

Expert Rev Anticancer Ther. 2008 Jun;8(6):887-93. doi: 10.1586/14737140.8.6.887. Review.

46.

Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.

Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM.

J Thorac Oncol. 2008 Feb;3(2):117-24. doi: 10.1097/JTO.0b013e3181622bef.

47.

Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.

Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM.

J Thorac Oncol. 2008 Feb;3(2):107-10. doi: 10.1097/JTO.0b013e3181630ece. Review.

48.

Inflammation and lung carcinogenesis: applying findings in prevention and treatment.

Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM.

Expert Rev Anticancer Ther. 2007 Oct;7(10):1405-21. Review.

PMID:
17944566
49.

Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy.

Reckamp KL, Figlin RA, Moldawer N, Pantuck AJ, Belldegrun AS, Burdick MD, Strieter RM.

J Immunother. 2007 May-Jun;30(4):417-24.

PMID:
17457216
50.

A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.

Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA.

Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3381-8.

Supplemental Content

Loading ...
Support Center